Seliciclib
Seliciclib
Seliciclib (pronounced: sel-ih-SIK-lib) is a small molecule inhibitor specifically designed to target and inhibit the activity of cyclin-dependent kinases (CDKs). It is currently under investigation for its potential use in the treatment of various types of cancer.
Etymology
The term "Seliciclib" is a coined name for this specific drug, with no known etymology. It is also known by its experimental code name, R-roscovitine.
Mechanism of Action
Seliciclib works by inhibiting the activity of CDKs, a group of protein kinases that are crucial for cell cycle regulation. By blocking these kinases, Seliciclib can halt the progression of the cell cycle, thereby inhibiting the growth and proliferation of cancer cells.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety and efficacy of Seliciclib in treating various types of cancer. These trials have shown promising results, with some patients experiencing significant reductions in tumor size and improved survival rates.
Related Terms
See Also
External links
- Medical encyclopedia article on Seliciclib
- Wikipedia's article - Seliciclib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski